Vaccination Report – 3 May 2022

1. Vaccine Implementation

• WHO's Emergency Use Listing(EUL) Vaccines (Last Updated 2 April 2022)

	Manufacturer	Name of Vaccine	NRA of Record	Vaccine type	
1	Pfizer-BioNTech (US)	BNT162b2/COMIRNATY Tozinameran (INN)	EMA,USFDA	mRNA	
2	AstraZeneca (UK)	AZD1222 Vaxzevria	EMA, MFDS KOREA, Japan MHLW/PMDA, Australia TGA, COFEPRIS(Mexico), ANMAT(Argentina)	Non ReplicatingViral vector	
3	Serum Institute of India (India)	Covishield (ChAdOx1_nCoV-19)	DCGI	Non Replicating Viral Vector	
4	Johnson &Johnson (US)	Ad26.CoV2.S	EMA, DCGI	Non ReplicatingViral vector	
5	Moderna (US)	mRNA-1273	EMA, USFDA, MFDS	DS mRNA	
6	Sinopharm Beijing (China)	SARS-CoV-2 Vaccine(Vero Cells)	NMPA	Inactivated virus (Vero Cells)	
7	Sinovac (China)	COVID-19 Vaccine (Vero Cells)	NMPA	Inactivated virus (Vero Cell)	
8	Bharat Biotech (India)	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN	DCGI Whole-Virion Inact (Vero Cell)		
9	Serum Institute of India (India)	NVX-CoV2373/Covovax	DCGI	Protein Subunit	
10	NÔVAVÁX (US)	NVX-CoV2373/Covovax	EMA	Protein Subunit	

• **38** Vaccines Approved by at Least One Country

Vaccine Type	mRNA	Non Replicating Viral vector	Inactivated virus	Protein Subunit	DNA	Virus-like Particles (VLP)	Total
In Use	3	7	11	15	1	1	38

Source: <u>https://covid19.trackvaccines.org/vaccines/</u> (Last Updated 2 May 2022)

 Vaccination against COVID-19 has now started in 218 locations (Source: <u>Our World in Data</u>. Last Updated 2 May 2022)

Location	Doses Given	Complete Initial Protocol (% of population)	Partly Vaccinated (% of population)
Worldwide	11.61 billion	4.66 billion (59.23 %)	5.16 billion (65.53 %)


About this data:

a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.

Share of people vaccinated against COVID-19, May 2, 2022

b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose). Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.

c: It only has full vaccination totals in some locations.




Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.


Share of people who completed the initial COVID-19 vaccination protocol, May 2, 2022



Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data – Last updated 3 May 2022 OurWorldInData.org/coronavirus • CC BY Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.



Source: Oxford COVID-19 Government Response Tracker, Blavatnik School of Government, University of Oxford – Last updated 3 May 2022 OurWorldInData.org/coronavirus • CC BY

2. Vaccine effectiveness against symptomatic infection for Alpha, Delta and Omicron variants

Vaccine Status	Vaccine Effectiveness		
	Alpha	Delta	Omicron
1 Dose (BNT162b2 or ChAdOx1 nCoV-19)	48.7% (95%Cl: 45.5-51.7%) ¹ 66%(BNT162b2) ⁴ 64% (ChAdOx1) ⁴	30.7% (95%CI: 25.2-35.7%) ¹ 56% (BNT162b2) ⁴ 67% (ChAdOx1) ⁴ 82% (95% CI:73- 91%) ⁷	

1 Dose (mRNA-1273)	83% ⁴	72% ⁴	
1 Dose(Sinopharm or Sinovac)		13.8%,(95%Cl: -60.2-54.8%) ³	
2 Doses (BNT162b2)	93.7% (95%CI: 91.6-95.3) ¹ 76% (95%CI: 69-81%) ² 89% ⁴	88% (95%CI: 85.3-90.1%) ¹ 42% (95% CI: 13-62%) ² 87% ⁴ 93% (95% CI: 88-97%/12-18Y) ⁵ 93% (95% CI: 88-97%) ⁷	50% (95% Cl: 35%–62%) ⁸
2 Doses (ChAdOx1 nCoV-19)	74.5% (95%CI: 68.4-79.4%) ¹	67.0% (95%Cl: 61.3-71.8%) ¹	
2 Doses (mRNA-1273)	86%, (95%Cl: 81-90.6%) ²	76%, (95% CI: 58-87%) ²	30.4% (95% CI: 5.0%-49.0%) ⁹
2 Doses(Sinopharm or Sinovac)		59.0%, (95%Cl: 16.0-81.6%) ³	
3 Doses (BNT162b2)		95.33% (SD 6.44) ⁶ 86.1% (95% Cl, 67.3 to 94.1) ¹¹	67.2% (95% CI: 66.5- 67.8%) at 2 to 4 weeks ¹⁰ 49.4% (95% CI, 47.1 to 51.6) ¹¹
3 Doses(mRNA-1273)			62.5% (95% CI: 56.2-67.9%) ⁹ 47.3% (95% CI, 40.7 to 53.3) ¹¹
2 Doses (BNT162b2) + 1Dose(mRNA-1273)			73.9% (95% CI: 73.1- 74.6%) at 2 to 4 weeks ¹⁰
2 Doses(ChAdOx1 nCoV- 19)+1Dose(BNT162b2)			62.4% (95% Cl, 61.8- 63.0) at 2 to 4 weeks ¹⁰
2 Doses (ChAdOx1 nCoV-19)+ 1Dose (mRNA-1273)			70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks ¹⁰

References:

- 1) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- 2) <u>Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of</u> <u>Alpha and Delta variant prevalence</u>
- 3) Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
- 4) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada
- 5) Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
- 6) <u>A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses</u> of CoronaVac
- 7) Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
- 8) Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- 9) Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
- 10) Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- 11) Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

3. Latest Relevant Articles

- Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
- <u>Understanding Vaccine Safety and the Roles of the FDA and the CDC</u>
- <u>Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination</u>
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

 Hospitalized patients with severe COVID-19 during the Omicron wave in Israel benefits of a fourth vaccine dose

4. Other Information

- BMJ: The benefits of large scale covid-19 vaccination
- <u>CDC: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies United</u> <u>States, September 2021–February 2022</u>